Continuous dopaminergic stimulation and novel formulations of dopamine agonists

Research output: Contribution to journalArticlepeer-review


There is now accumulating evidence that the combination of progressive pathology of Parkinson's disease, the change in drug pharmacodynamics, and the pulsatile manner in which short-acting dopaminergic agents stimulate striatal dopamine receptors are the key contributing factors to the priming of the basal ganglia for induction of motor complications. Long-acting drugs provide a more physiological dopaminergic stimulation. Dopamine agonists have been extensively used as monotherapy and add-on therapy to levodopa to treat Parkinson's disease in the early stage and with motor complications. Today, the new long-acting formulation offers the advantages of an easy use and a more continuous delivery of drug. In this paper the role of new formulations of dopamine agonists in the treatment of parkinsonian patients at different stages of the disease is reviewed.

Original languageEnglish
JournalJournal of Neurology
Issue numberSUPPL. 2
Publication statusPublished - May 2011


  • Continuous dopaminergic stimulation
  • Dopamine agonist
  • Dyskinesia
  • Motor complications
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology


Dive into the research topics of 'Continuous dopaminergic stimulation and novel formulations of dopamine agonists'. Together they form a unique fingerprint.

Cite this